PENPULIMAB KCQX
(Penpulimab)Phase 3Monoclonal antibody
PENPULIMAB KCQX is a monoclonal antibody that works as a Programmed Cell Death Protein 1 Inhibitor.[2] It is being investigated across 11 indications, with its most advanced program in Phase 3.[1]
PENPULIMAB KCQX is one of 328 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.
11
Indications
27
Total Trials
14
Active Trials
327
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
375 competitors in Lymphoma
#DrugCompanyPhaseTrials
1PENPULIMAB KCQX
AAkeso
Phase 3
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma3 trials
Lymphoma3 trials
Non-Small Cell Lung Cancer2 trials
Pancreatic Cancer2 trials
13 more indications
Efficacy and Safety2 trials
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06516978·528 enrolled
Anlotinib2 trials
Metastatic Colorectal Cancer1 trial
Second-line Treatment1 trial
Advanced Malignant Tumors1 trial
Locally-advanced Rectal Cancer1 trial
Nasopharyngeal Carcinoma1 trial
Central Nervous System Lymphoma1 trial
Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05347641·23 enrolled
Adenocarcinoma1 trial
Colorectal Cancer1 trial
Breast Cancer1 trial
Head and Neck Squamous Cell Carcinoma1 trial
A Phase II Clinical Study of Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable Head and Neck Squamous Cell Carcinoma
Active, not recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06081673·72 enrolled
Primary Central Nervous System Lymphoma1 trial
Regulatory
FDA Approval Timeline[4]
Apr 23, 2025
PENPULIMAB KCQX
BLA BLA761258
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Penpulimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]